Menopause and your brain: what the science actually says about oestrogen and Alzheimer’s

Menopause and your brain: what the science actually says about oestrogen and Alzheimer’s

If you have spent any time online lately, you have probably seen the headlines. Menopause “shrinks your brain.” Oestrogen loss “causes Alzheimer’s.” Hormone therapy is the thing standing between you and dementia.

I want to walk you through what the research actually shows, because the real story is more interesting, more reassuring, and far more useful than the scary version. And I want to start with something I will keep coming back to: menopause is not a disease. It is a normal life transition that every woman who lives long enough will go through. Your brain is not breaking. It is adapting.

Let’s get into it.

What you need to know

The menopause transition is a real brain event, not just a reproductive one, and for most women it is a transition the brain adapts to rather than a slide into decline. The things that protect your long-term brain health are mostly the same things that protect your heart. And hormone therapy is an excellent tool for managing symptoms in the right women, but it is not a dementia prevention strategy. That is the whole post in three sentences. Here is the detail.

Oestrogen does real work in the brain

Oestradiol, the main form of oestrogen in your reproductive years, is not just a reproductive hormone. In the brain it helps regulate how neurons use glucose for energy, supports the mitochondria that power your brain cells, helps maintain the connections between neurons, and helps keep inflammation in check.

So when oestrogen falls during perimenopause, it makes sense that the brain goes through a period of adjustment. This is the part the research has caught up on beautifully. Dr Lisa Mosconi and her team at Weill Cornell have used brain imaging to follow women across the transition, and they can actually see changes in brain energy metabolism and structure that line up with the symptoms women describe. The brain fog, the word-finding moments, the disrupted sleep. These are not imagined. The biology matches the experience.

But here is the part the scary headlines tend to leave out. Mosconi’s own imaging work shows that for most women, the brain re-stabilises after menopause. It finds a new equilibrium. Some markers of brain energy even partly recover, and cognition in the general population does not fall off a cliff at 51. The perimenopausal brain is better understood as a brain in transition than a brain in decline.

That distinction matters enormously, and it is why I will not use language like “menopause damages your brain.” It does not reflect what the data show.

“But aren’t women twice as likely to get Alzheimer’s?”

This is one of the most misunderstood statistics in the whole conversation, so let me give it the context it deserves.

It is true that around two thirds of people living with Alzheimer’s are women. But the biggest single reason is not female biology. It is that women live longer than men, and age is by far the strongest risk factor for dementia. In 2024 the life expectancy gap was nearly five years. When you compare men and women at the same age, the difference in risk largely shrinks. Women’s higher lifetime risk emerges mostly because more women survive into their 80s and 90s, which are the highest risk decades.

To put the age effect in perspective: dementia affects roughly 5 percent of people aged 65 to 74, around 13 percent of those aged 75 to 84, and about a third of people aged 85 and over. Age is the headline. Sex is a footnote by comparison.

There is a genuine biological piece too. The APOE4 gene, the most common genetic risk factor for late-onset Alzheimer’s, does appear to raise risk a little more in women than men, but the research shows this is concentrated in a fairly narrow age window around 65 to 75, not across the whole lifespan. And carrying APOE4 is a risk factor, not a sentence. Plenty of people carry it and never develop dementia, and the lifestyle factors we will get to appear to help regardless of which genes you carry.

So the honest version is this. Most women will not develop dementia. Risk rises steeply with age. And the things you do in midlife can shift that risk in your favour.

Where does hormone therapy fit?

This is the question I get asked most, and I want to be really clear and really honest, because there is a lot of confident messaging out there that runs ahead of the evidence.

Menopausal hormone therapy is the most effective treatment we have for moderate to severe hot flushes and night sweats, and for most women who start it within ten years of menopause or before age 60, the benefit-to-risk balance for symptom relief is favourable. That is well established and supported by the menopause societies.

What hormone therapy is not, on current evidence, is a dementia prevention strategy. The major menopause guidelines are explicit that hormone therapy should not be prescribed at any age for the purpose of preventing cognitive decline or dementia.

You may have heard about the “critical window” or “timing” idea, the theory that hormone therapy might protect the brain if started early but harm it if started late. It is a real and actively researched hypothesis. The large trial that raised concern about dementia risk only studied women who started therapy after 65, and more recent analyses of women who start earlier suggest a neutral or possibly slightly favourable effect. But this is unsettled. The studies that look reassuring are mostly observational, which means they can be skewed by the fact that women who take hormone therapy tend to be healthier to begin with. We do not have the definitive trial yet.

So if you are weighing up hormone therapy, the right reason to consider it is symptoms and quality of life, in a conversation with a doctor who knows your history. Not as a way to prevent dementia.

The good news: what you can actually do

Here is the part I find most empowering, and it is backed by some of the strongest evidence in the whole field.

In 2024 the Lancet Commission, a major international panel, concluded that around 45 percent of dementia cases worldwide are linked to 14 modifiable risk factors across life. That figure is a theoretical maximum rather than a personal guarantee, but the direction is powerful. A large share of dementia risk is connected to the way we live, not to fate or genes alone.

And most of those factors are exactly the things that support you through the menopause transition anyway. Notice that menopause and hormone therapy are not on that list. The Commission looked and concluded the evidence was not clear enough to include them. The levers that are on the list are far more in your control.

The big midlife ones:

Move your body, and lift things. Combine aerobic exercise with strength training. One long-running study of women followed for over 40 years found that those with high midlife fitness had a dramatically lower risk of dementia than their moderately fit peers. That is observational, so we hold it loosely, but it points the same way as everything else.

Look after your blood pressure, cholesterol and blood sugar. High LDL cholesterol was added as a new risk factor in 2024, and blood pressure has long been on the list. A major trial showed that lowering blood pressure reduced the rate of mild cognitive impairment. These are also the numbers that shift cardiovascular risk, which climbs for women after menopause.

Protect your sleep. Deep sleep is when the brain does much of its housekeeping. Treating night sweats and addressing sleep problems is brain care, not a luxury.

Eat a Mediterranean-style pattern. This is the most consistent dietary evidence we have. One 2025 study even found the benefit held strongly in women carrying the highest-risk version of the APOE4 gene, which suggests good food may partly offset genetic risk.

Look after your hearing, stay connected, go easy on alcohol, and don’t smoke. Hearing loss and untreated cholesterol carry the largest individual weights in the 2024 model, and social connection matters more than most people realise.

The reassuring thread through all of this is that the most powerful trial evidence we have is not for a pill. It is for combining these everyday behaviours. Big multidomain lifestyle studies have shown measurable cognitive benefits, and importantly the benefits showed up regardless of sex or APOE4 status. This stuff works for everyone.

The bottom line

Menopause is a transition, not a disease. Your brain changes through it, and then for most women it adapts. The statistics that sound frightening usually have a calmer explanation once you add the context. Hormone therapy is a good tool for symptoms in the right women, but it is not a brain insurance policy.

The real insurance policy is the way you live through your 40s, 50s and 60s. Move, lift, sleep, eat well, look after your heart numbers, stay connected, protect your hearing. None of it is glamorous. All of it works. And it is never too late to start.

You are not running out of time. You are right in the window where this matters most.

This post is general education, not medical advice. If you are considering hormone therapy or have concerns about your brain health or family history, please have an individual conversation with your GP or a menopause-informed clinician.

References

  1. Mosconi L, Berti V, Quinn C, et al. Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery. PLoS One. 2017;12(10):e0185926. https://pubmed.ncbi.nlm.nih.gov/29016679/

  2. Mosconi L, Berti V, Dyke J, et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Scientific Reports. 2021;11:10867.

  3. Mosconi L, Williams S, Carlton C, et al. Sex-specific associations of serum cortisol with brain biomarkers of Alzheimer’s risk; and brain oestrogen receptor density across the menopause transition (18F-fluoroestradiol PET). Scientific Reports. 2024;14:12680.

  4. Brinton RD. The healthy cell bias of oestrogen action: mitochondrial bioenergetics and neurological implications. Trends in Neurosciences. 2008;31(10):529-537.

  5. Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. Perimenopause as a neurological transition state. Nature Reviews Endocrinology. 2015;11(7):393-405. https://www.nature.com/articles/nrendo.2015.82

  6. Thurston RC, Aizenstein HJ, Derby CA, Sejdic E, Maki PM. Menopausal hot flashes and white matter hyperintensities. Menopause. 2016;23(1):27-32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4673042/

  7. Thurston RC, Maki P, Chang Y, et al. Menopausal vasomotor symptoms and plasma Alzheimer disease biomarkers. American Journal of Obstetrics and Gynecology. 2024;230(3):342.e1-342.e8. https://pubmed.ncbi.nlm.nih.gov/37939982/

  8. Neu SC, Pa J, Kukull W, et al. Apolipoprotein E genotype and sex risk factors for Alzheimer disease: a meta-analysis. JAMA Neurology. 2017;74(10):1178-1189. https://pubmed.ncbi.nlm.nih.gov/28846757/

  9. Hohman TJ, Dumitrescu L, Barnes LL, et al. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. JAMA Neurology. 2018;75(8):989-998.

  10. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study (WHIMS). JAMA. 2003;289(20):2651-2662.

  11. Rapp SR, Espeland MA, Hogan P, et al. Cognitive function and conjugated equine estrogens: the Women’s Health Initiative Memory Study follow-up. Journal of Alzheimer’s Disease. 2010;20(s2). https://pubmed.ncbi.nlm.nih.gov/19932751/

  12. Nerattini M, Jett S, Andy C, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer’s disease and dementia. Frontiers in Aging Neuroscience. 2023;15:1260427. https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2023.1260427/full

  13. Henderson VW, St John JA, Hodis HN, et al. Cognitive effects of estradiol after menopause: a randomized trial of the timing hypothesis (ELITE). Neurology. 2016;87(7):699-708.

  14. Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: KEEPS-Cognitive and Affective Study. PLoS Medicine. 2015;12(6):e1001833.

  15. The 2022 hormone therapy position statement of The North American Menopause Society (now The Menopause Society). Menopause. 2022;29(7):767-794. https://journals.lww.com/menopausejournal/abstract/2022/07000/the_2022_hormone_therapy_position_statement_of_the.4.aspx

  16. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404(10452):572-628. https://www.thelancet.com/commissions-do/dementia-prevention-intervention-and-care

  17. Baker LD, Espeland MA, Whitmer RA, et al. Structured versus self-guided multidomain lifestyle interventions for global cognitive function: the U.S. POINTER randomized clinical trial. JAMA. 2025;334(8):681-691. https://aaic.alz.org/releases-2025/us-pointer-study-results-announced.asp

  18. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). The Lancet. 2015;385(9984):2255-2263.

  19. SPRINT MIND Investigators. Effect of intensive vs standard blood pressure control on probable dementia and mild cognitive impairment (SPRINT MIND). JAMA. 2019;321(6):553-561. https://www.tandfonline.com/doi/full/10.1080/08037051.2019.1678261

  20. Hörder H, Johansson L, Guo X, et al. Midlife cardiovascular fitness and dementia: a 44-year longitudinal population study in women. Neurology. 2018;90(15):e1298-e1305. https://pmc.ncbi.nlm.nih.gov/articles/PMC5894933/

  21. Liu YH, et al. Mediterranean diet, genetic susceptibility, and risk of dementia: a 34-year cohort study. Nature Medicine. 2025;31:3790-3800. https://www.cnn.com/2025/08/25/health/mediterranean-diet-dementia-apoe4-wellness

  22. Chêne G, Beiser A, Au R, et al. Gender and incidence of dementia in the Framingham Heart Study from mid-adult life. Alzheimer’s & Dementia. 2015;11(3):310-320. https://pmc.ncbi.nlm.nih.gov/articles/PMC4092061/

  23. Fang M, Hu J, Coresh J, et al. Lifetime risk of dementia after age 55. Nature Medicine. 2025.

  24. Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia. 2024. https://www.brightfocus.org/alzheimers/facts-figures/

  25. Arias E, Xu J. United States Life Tables, 2024. National Center for Health Statistics Data Brief No. 548, January 2026. https://www.cdc.gov/nchs/data/databriefs/db548.pdf

  26. Study of Women’s Health Across the Nation (SWAN). Hot flashes fact sheet. https://www.swanstudy.org/